References
1. Pai, K., et al., Optimising alkalinisation and its effect on QRS narrowing in tricyclic antidepressant poisoning. 2022. 88 (2): p. 723-733.
2. Arango-Dávila, C.A. and H.G. Rincón-Hoyos, Depressive disorder, anxiety disorder and chronic pain: Multiple manifestations of a common clinical and pathophysiological core. Revista Colombiana de Psiquiatría (English Edition), 2018. 47 (1): p. 46-55.
3. Soleimani, V., et al., Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytother Res, 2019. 33 (6): p. 1627-1638.
4. Hadi, A., et al., The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Complement Ther Med, 2018. 41 : p. 311-319.
5. Gummin, D.D., et al., 2020 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila), 2021. 59 (12): p. 1282-1501.
6. Gummin, D.D., et al., 2017 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila), 2018. 56 (12): p. 1213-1415.
7. Elsamadisi, P., A. Sclafani, and I.M. Eche, Delayed Cardiotoxicity From a Massive Nortriptyline Overdose Requiring Prolonged Treatment. J Pharm Pract, 2020. 33 (4): p. 543-547.
8. Giwa, A. and E. Oey, The return of an old nemesis: Survival after severe tricyclic antidepressant toxicity, a case report. Toxicol Rep, 2018. 5 : p. 357-362.
9. Pierog, J.E., et al., Tricyclic antidepressant toxicity treated with massive sodium bicarbonate. Am J Emerg Med, 2009. 27 (9): p. 1168.e3-7.
10. Breyer-Pfaff, U., et al., Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. 1982. 76 (3): p. 240-244.
11. Lee, S.Y., et al., A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication. J Korean Med Sci, 2004. 19 (5): p. 750-2.
12. Shim JC, G.B., Park JH, Yoon YR, Sin JG, Kim JI, Ahn DS, Kim YK, Cha IJ, Kim YH., Combined therapy of paroxetine and tricyclic antidepressant in depression of schizophrenic patients. Korean Neuropsychiatr Assoc, 1997. 36 .
13. Karimi, G., et al., ”Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci, 2011. 14 (4): p. 308-17.
14. Wu, J.-W., L.-C. Lin, and T.-H. Tsai, Drug–drug interactions of silymarin on the perspective of pharmacokinetics. Journal of Ethnopharmacology, 2009. 121 (2): p. 185-193.